OmniAb's core business segment centers around its proprietary antibody discovery platform. This platform leverages transgenic animals (OmniRat, OmniChicken, and OmniMouse) genetically engineered to produce human antibodies. The company utilizes high-throughput screening and advanced in silico tools (OmniDeep) to identify and optimize therapeutic antibodies for its partners. Research and development activities include continuous improvement of the transgenic animal models, development of novel screening methodologies, and refinement of AI/ML algorithms for antibody selection. The platform supports drug discovery across various therapeutic areas, including oncology, immunology, and infectious diseases. The impact is accelerated drug development timelines and the potential for more effective therapies. OmniAb's market position is strong due to its diverse antibody repertoires and ability to generate fully human antibodies. Future opportunities include expanding the platform to discover bispecific antibodies (OmniFlic, OmniClic) and antibodies for complex targets (OmniTaur). Partnerships with pharmaceutical and biotech companies are crucial for clinical trials and commercialization. Regulatory aspects involve compliance with FDA guidelines for antibody-based therapeutics.